These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24788735)

  • 1. Integrated care: nonfasting screening for cardiovascular risk among individuals taking second-generation antipsychotics.
    Vanderlip ER; Chwastiak LA; McCarron RM
    Psychiatr Serv; 2014 May; 65(5):573-6. PubMed ID: 24788735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study.
    Mangurian C; Schillinger D; Newcomer JW; Vittinghoff E; Essock S; Zhu Z; Dyer W; Schmittdiel J
    J Gen Intern Med; 2018 Jan; 33(1):79-86. PubMed ID: 29090381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening, diagnosis, and treatment of dyslipidemia among persons with persistent mental illness: a literature review.
    Vanderlip ER; Fiedorowicz JG; Haynes WG
    Psychiatr Serv; 2012 Jul; 63(7):693-701. PubMed ID: 22588231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of care for cardiovascular disease and diabetes amongst individuals with serious mental illness and those using antipsychotic medications.
    Scott D; Platania-Phung C; Happell B
    J Healthc Qual; 2012; 34(5):15-21. PubMed ID: 22092725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.
    Straker D; Correll CU; Kramer-Ginsberg E; Abdulhamid N; Koshy F; Rubens E; Saint-Vil R; Kane JM; Manu P
    Am J Psychiatry; 2005 Jun; 162(6):1217-21. PubMed ID: 15930076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of monitoring and management guidelines for second-generation antipsychotics.
    Sernyak MJ
    J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor.
    Jerrell JM; McIntyre RS; Black GB
    Psychiatr Serv; 2012 Mar; 63(3):202-4. PubMed ID: 22388526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications.
    Mangurian C; Newcomer JW; Vittinghoff E; Creasman JM; Knapp P; Fuentes-Afflick E; Schillinger D
    JAMA Intern Med; 2015 Dec; 175(12):1977-9. PubMed ID: 26551047
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary care issues in patients with mental illness.
    Kiraly B; Gunning K; Leiser J
    Am Fam Physician; 2008 Aug; 78(3):355-62. PubMed ID: 18711951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and mental illness.
    Newcomer JW
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.
    Park T; Usher K; Foster K
    Int J Ment Health Nurs; 2011 Dec; 20(6):428-37. PubMed ID: 21564457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.
    Newcomer JW
    J Clin Psychiatry; 2009; 70 Suppl 3():30-6. PubMed ID: 19570499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions to Improve Metabolic Risk Screening Among Adult Patients Taking Antipsychotic Medication: A Systematic Review.
    Melamed OC; Wong EN; LaChance LR; Kanji S; Taylor VH
    Psychiatr Serv; 2019 Dec; 70(12):1138-1156. PubMed ID: 31522630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics.
    Fetter JC; Brunette M; Green AI
    Clin Schizophr Relat Psychoses; 2013; 7(2):73-77A. PubMed ID: 23367502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for metabolic risk among patients with severe mental illness and diabetes: a national comparison.
    Mitchell AJ; Hardy SA
    Psychiatr Serv; 2013 Oct; 64(10):1060-3. PubMed ID: 24081407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction: cardiovascular disease and metabolic risk factors in patients with mental illness.
    Newcomer JW
    CNS Spectr; 2008 Jun; 13(6 Suppl 10):1-14. PubMed ID: 18567978
    [No Abstract]   [Full Text] [Related]  

  • 19. Is family history a useful tool for detecting children at risk for diabetes and cardiovascular diseases? A public health perspective.
    Valdez R; Greenlund KJ; Khoury MJ; Yoon PW
    Pediatrics; 2007 Sep; 120 Suppl 2():S78-86. PubMed ID: 17767009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.